Cargando…

B-cell responses to vaccination with BNT162b2 and mRNA-1273 6 months after second dose

OBJECTIVES: To examine the state of B-cell immunity 6 months after the second vaccination against SARS-CoV-2 in comparison to the state observed 2 weeks after vaccination. METHODS: Sera of 439 participants, whose immune responses to two doses of an mRNA-based vaccine (BNT162b2 or mRNA-1273) were pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Markewitz, Robert, Pauli, Daniela, Dargvainiene, Justina, Steinhagen, Katja, Engel, Sarah, Herbst, Victor, Zapf, Dorinja, Krüger, Christina, Sharifzadeh, Shahpour, Schomburg, Benjamin, Leypoldt, Frank, Rupp, Jan, Görg, Siegfried, Junker, Ralf, Wandinger, Klaus-Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897957/
https://www.ncbi.nlm.nih.gov/pubmed/35259531
http://dx.doi.org/10.1016/j.cmi.2022.02.028
_version_ 1784663542121627648
author Markewitz, Robert
Pauli, Daniela
Dargvainiene, Justina
Steinhagen, Katja
Engel, Sarah
Herbst, Victor
Zapf, Dorinja
Krüger, Christina
Sharifzadeh, Shahpour
Schomburg, Benjamin
Leypoldt, Frank
Rupp, Jan
Görg, Siegfried
Junker, Ralf
Wandinger, Klaus-Peter
author_facet Markewitz, Robert
Pauli, Daniela
Dargvainiene, Justina
Steinhagen, Katja
Engel, Sarah
Herbst, Victor
Zapf, Dorinja
Krüger, Christina
Sharifzadeh, Shahpour
Schomburg, Benjamin
Leypoldt, Frank
Rupp, Jan
Görg, Siegfried
Junker, Ralf
Wandinger, Klaus-Peter
author_sort Markewitz, Robert
collection PubMed
description OBJECTIVES: To examine the state of B-cell immunity 6 months after the second vaccination against SARS-CoV-2 in comparison to the state observed 2 weeks after vaccination. METHODS: Sera of 439 participants, whose immune responses to two doses of an mRNA-based vaccine (BNT162b2 or mRNA-1273) were previously characterized, was examined for anti-S1 IgG and IgA, anti-NCP IgG and neutralizing antibodies (nAb), and antinuclear antibodies (ANA). RESULTS: Levels of all examined markers decreased significantly from 2 weeks to 6 months after second vaccination (anti-S1 IgG: 3744 ± 2571.4 vs. 253 ± 144 binding antibody units (BAU)/mL; anti-S1 IgA: 12 ± 0 vs. 1.98 ± 1.75 optical density (OD) ratio; nAb: 100% ± 0% vs. 82% ± 19.3%), the vast majority of participants retaining reactive levels of anti-S1 IgG (436/439) and anti-S1 IgA (334/439) at 6 months. Immune responses were stronger for mRNA-1273 compared with BNT162b2 (anti-S1 IgG: 429 ± 289 vs. 243 ± 143 BAU/mL; anti-S1 IgA: 5.38 ± 3.91 vs. 1.89 ± 1.53 OD ratio; nAb: 90.5% ± 12.6% vs. 81% ± 19.3%). There was no meaningful influence of sex and age on the examined markers. There was a strong correlation between anti-S1 IgG and the surrogate neutralization assay (rho = 0.91, p <0.0001), but not for for IgA and the surrogate neutralization assay (rho = 0.52, p <0.0001). There was a ceiling effect for the association between anti-S1 IgG titres and the inhibition of binding between S1 and ACE2. ANA prevalence was unchanged from 2 weeks to 6 months after the second vaccination (87/498 vs. 77/435), as were the median ANA titres (1:160 vs. 1:160). DISCUSSION: Although the clinical consequences of decreasing anti-SARS-CoV-2 antibody titres cannot be estimated with certainty, a lowered degree of clinical protection against SARS-CoV-2 is possible. Persistently stronger responses to mRNA-1273 suggest that it might confer greater protection than BNT162b2, even 6 months after the second vaccination. Neither examined vaccinations induced ANA within the examined time frame.
format Online
Article
Text
id pubmed-8897957
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-88979572022-03-07 B-cell responses to vaccination with BNT162b2 and mRNA-1273 6 months after second dose Markewitz, Robert Pauli, Daniela Dargvainiene, Justina Steinhagen, Katja Engel, Sarah Herbst, Victor Zapf, Dorinja Krüger, Christina Sharifzadeh, Shahpour Schomburg, Benjamin Leypoldt, Frank Rupp, Jan Görg, Siegfried Junker, Ralf Wandinger, Klaus-Peter Clin Microbiol Infect Original Article OBJECTIVES: To examine the state of B-cell immunity 6 months after the second vaccination against SARS-CoV-2 in comparison to the state observed 2 weeks after vaccination. METHODS: Sera of 439 participants, whose immune responses to two doses of an mRNA-based vaccine (BNT162b2 or mRNA-1273) were previously characterized, was examined for anti-S1 IgG and IgA, anti-NCP IgG and neutralizing antibodies (nAb), and antinuclear antibodies (ANA). RESULTS: Levels of all examined markers decreased significantly from 2 weeks to 6 months after second vaccination (anti-S1 IgG: 3744 ± 2571.4 vs. 253 ± 144 binding antibody units (BAU)/mL; anti-S1 IgA: 12 ± 0 vs. 1.98 ± 1.75 optical density (OD) ratio; nAb: 100% ± 0% vs. 82% ± 19.3%), the vast majority of participants retaining reactive levels of anti-S1 IgG (436/439) and anti-S1 IgA (334/439) at 6 months. Immune responses were stronger for mRNA-1273 compared with BNT162b2 (anti-S1 IgG: 429 ± 289 vs. 243 ± 143 BAU/mL; anti-S1 IgA: 5.38 ± 3.91 vs. 1.89 ± 1.53 OD ratio; nAb: 90.5% ± 12.6% vs. 81% ± 19.3%). There was no meaningful influence of sex and age on the examined markers. There was a strong correlation between anti-S1 IgG and the surrogate neutralization assay (rho = 0.91, p <0.0001), but not for for IgA and the surrogate neutralization assay (rho = 0.52, p <0.0001). There was a ceiling effect for the association between anti-S1 IgG titres and the inhibition of binding between S1 and ACE2. ANA prevalence was unchanged from 2 weeks to 6 months after the second vaccination (87/498 vs. 77/435), as were the median ANA titres (1:160 vs. 1:160). DISCUSSION: Although the clinical consequences of decreasing anti-SARS-CoV-2 antibody titres cannot be estimated with certainty, a lowered degree of clinical protection against SARS-CoV-2 is possible. Persistently stronger responses to mRNA-1273 suggest that it might confer greater protection than BNT162b2, even 6 months after the second vaccination. Neither examined vaccinations induced ANA within the examined time frame. European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2022-07 2022-03-05 /pmc/articles/PMC8897957/ /pubmed/35259531 http://dx.doi.org/10.1016/j.cmi.2022.02.028 Text en © 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original Article
Markewitz, Robert
Pauli, Daniela
Dargvainiene, Justina
Steinhagen, Katja
Engel, Sarah
Herbst, Victor
Zapf, Dorinja
Krüger, Christina
Sharifzadeh, Shahpour
Schomburg, Benjamin
Leypoldt, Frank
Rupp, Jan
Görg, Siegfried
Junker, Ralf
Wandinger, Klaus-Peter
B-cell responses to vaccination with BNT162b2 and mRNA-1273 6 months after second dose
title B-cell responses to vaccination with BNT162b2 and mRNA-1273 6 months after second dose
title_full B-cell responses to vaccination with BNT162b2 and mRNA-1273 6 months after second dose
title_fullStr B-cell responses to vaccination with BNT162b2 and mRNA-1273 6 months after second dose
title_full_unstemmed B-cell responses to vaccination with BNT162b2 and mRNA-1273 6 months after second dose
title_short B-cell responses to vaccination with BNT162b2 and mRNA-1273 6 months after second dose
title_sort b-cell responses to vaccination with bnt162b2 and mrna-1273 6 months after second dose
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897957/
https://www.ncbi.nlm.nih.gov/pubmed/35259531
http://dx.doi.org/10.1016/j.cmi.2022.02.028
work_keys_str_mv AT markewitzrobert bcellresponsestovaccinationwithbnt162b2andmrna12736monthsafterseconddose
AT paulidaniela bcellresponsestovaccinationwithbnt162b2andmrna12736monthsafterseconddose
AT dargvainienejustina bcellresponsestovaccinationwithbnt162b2andmrna12736monthsafterseconddose
AT steinhagenkatja bcellresponsestovaccinationwithbnt162b2andmrna12736monthsafterseconddose
AT engelsarah bcellresponsestovaccinationwithbnt162b2andmrna12736monthsafterseconddose
AT herbstvictor bcellresponsestovaccinationwithbnt162b2andmrna12736monthsafterseconddose
AT zapfdorinja bcellresponsestovaccinationwithbnt162b2andmrna12736monthsafterseconddose
AT krugerchristina bcellresponsestovaccinationwithbnt162b2andmrna12736monthsafterseconddose
AT sharifzadehshahpour bcellresponsestovaccinationwithbnt162b2andmrna12736monthsafterseconddose
AT schomburgbenjamin bcellresponsestovaccinationwithbnt162b2andmrna12736monthsafterseconddose
AT leypoldtfrank bcellresponsestovaccinationwithbnt162b2andmrna12736monthsafterseconddose
AT ruppjan bcellresponsestovaccinationwithbnt162b2andmrna12736monthsafterseconddose
AT gorgsiegfried bcellresponsestovaccinationwithbnt162b2andmrna12736monthsafterseconddose
AT junkerralf bcellresponsestovaccinationwithbnt162b2andmrna12736monthsafterseconddose
AT wandingerklauspeter bcellresponsestovaccinationwithbnt162b2andmrna12736monthsafterseconddose